Monograph Details
|
|
Gastrointestinal Tract
> Hyperacidity, GERD, and ulcers
|
|
PEPCID INJECTION |
| Manufacturer |
|
Merck & Co., Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
H2 blocker. |
| Generic Name |
|
Famotidine 10mg/mL; soln for IV inj or infusion after dilution; multidose vials contain benzyl alcohol. |
| Also |
• PEPCID
• PEPCID INJECTION PREMIXED
• PEPCID SUSPENSION
|
| Indications |
|
Hospitalized patients with pathological hypersecretory conditions, intractable ulcers, or as a short-term alternative to oral dosage forms. |
| Children |
|
See literature. Give by IV inj over 2 minutes or infuse over 15 minutes. <1yr: not recommended. 1–16yrs: initially 0.25mg/kg every 12hrs; max 40mg/day. |
| Adults |
|
Give by IV inj over 2 minutes or infuse over 15–30 minutes. 20mg every 12 hrs. |
| Precautions |
|
Moderate to severe renal insufficiency (CrCl <50mL/min): reduce dose or prolong dosing interval. Pregnancy (Cat.B). Nursing mothers: not recommended. |
| Interactions |
|
May give antacids concomitantly. |
| Adverse Reactions |
|
Headache, dizziness, constipation, diarrhea, somnolence, seizures, palpitations, depression, inj site reactions. |
| How Supplied |
Tabs—30, 90, 100, 1000
Susp—50mL
Inj single-dose vials (2mL)—10
Multidose vials (4mL)—1
Multidose vials (20mL)—1, 10
Premixed (50mL)—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
